Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153470 (Spleen)
 4,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Specific tolerance to phosphorylcholine (PC) was induced in BALB/c mice by two methods. Neonatal mice received a single injection of either: 1)PnC, the C-polysaccharide from S. pneumoniae, R36a vaccine which has PC as a major antigenic determinant or 2) ARA, an homologous antibody directed against the receptor for PC. Spleen cells from animals treated as neonates with either PnC or ARA were specifically suppressed for the response to PC antigens in vitro. In addition, cells from either group of unresponsive animals co-cultured with spleen cells of normal BALB/c mice markedly suppressed the response of the normal cells to PC. Greater than 90% inhibition of the plaque-forming cell response was obtained when unresponsive cells were mixed with normal cells in ratios of 1:1 or greater. Equal numbers of cells from animals made unresponsive by PnC or ARA produced an equivalent degree of suppression. Neither supernatants of cultures nor sera of animals of either unresponsive group suppressed the response of normal spleen cells to PC. Suppression by cells from both groups of tolerant mice was eliminated by treatment with anti-Thy 1.2 serum and C. Presumably, a common cell is responsible for suppression caused by cells from mice made unresponsive by either procedure.
 ...
PMID:Suppressor T cells: presence in mice rendered tolerant by neonatal treatment with anti-receptor antibody or antigen. 7 7

Spleen cells from the BDF1 generation of DBA male X C57Bl/6 female matings sensitized with sheep erythrocytes (SRBC) were exposed to various concentrations of ARA, PGE2, and PGF2alpha for 90 minutes in vitro at 37 degrees C. Following exposure these sensitized spleen cells were then examined in the hemolytic plaque assay. No changes were demonstrated in the number of plaque forming cells (PFC) with 0.1 microgram/ml of ARA treatment. However, an increase in the number of PFC occurred with increasing concentrations of ARA. A significant increase (p less than 0.01) in PFC (59%) was shown with 10.0 microgram/ml of ARA. PGE2 treatment at 10.0 and 100.0 microgram/ml showed no evidence of increase, but a slight decrease (10%) was shown with 100.0 microgram/ml. On the other hand, exposure to PGF2alpha showed a significant increase (p less than 0.05) in PFC at the 10.0 microgram/ml (35%) and the 100.0 microgram/ml (29% levels, respectively. The data suggest that both ARA and PGF2alpha enhanced PFC formation.
 ...
PMID:Effect of arachidonic acid (ARA), prostaglandins E2 (PGE2), and F2alpha (PGF2alpha) on sensitized spleen cells in the hemolytic plaque assay. 36 70